HLX 07

Drug Profile

HLX 07

Alternative Names: HLX07

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Henlius Biotech
  • Class Antineoplastics; Biobetters; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Colorectal cancer; Head and neck cancer

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Taiwan (Parenteral) (NCT02648490)
  • 11 Jan 2016 Henlix plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA and Taiwan (Parenteral) (NCT02648490)
  • 18 Jun 2015 Preclinical trials in Colorectal cancer in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top